Ongoing clinical trials will evaluate the use of brigatinib for treatment-naive ALK-positive NSCLC patients, and there is also a trial evaluating the use of brigatinib after disease progression on second-generation ALK inhibitors (ceritinib and alectinib), which is currently accruing patients. This evidence concerns the gene ALK and non-small cell lung carcinoma.